Anaverse™ Glenoid System and Its Instrumentation

Anaverse™ Glenoid System and Its Instrumentation - Retrospective and Prospective, Non-Controlled Post Market Clinical Follow-Up Study

The objectives of this study are to confirm safety, performance and clinical benefits of the Anaverse™ Glenoid System and its instrumentation by analysis of standard scoring systems, radiographs and adverse event records.

Study Overview

• Status: Terminated
• Conditions: Rotator Cuff Injuries; Shoulder Pain; Arthropathy; Arthroplasty Complications
• Intervention / Treatment: Device: Anaverse Shoulder System

Detailed Description

The safety of the system will be assessed by monitoring the frequency and incidence of adverse events.

The performance and clinical benefits will be evaluated by assessment of the overall pain and functional performance, survival, and radiographic parameters of all enrolled study subjects.

The primary endpoint is defined by the survival of the implant system at 2 years which is based on removal or intended removal of the Anaverse™ Glenoid System baseplate and will be determined by using the Kaplan Meier method.

• Study Type: Observational
• Enrollment (Actual): 20

Contacts and Locations

Study Locations

• Switzerland
  • Zurich, Switzerland, 8008
    • Balgrist University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

Patients suffering from severe shoulder pain and disability indicated for implantation of the Anaverse™ Glenoid System in cases of total shoulder arthroplasty in reversed configuration. Patients who underwent total shoulder arthroplasty conversion from anatomical to reversed will be enrolled for subgroup analysis. Patients must meet all inclusion and none of the exclusion criteria.

Description

Inclusion Criteria:

• Patient is 18-75 years of age, inclusive.
• Patient is skeletally mature.
• Patient is capable of understanding the doctor's explanations, following his instructions and is able to participate in the follow-up program.
• Patient must have signed EC-approved informed consent.
• Patient requires a primary reversed total shoulder arthroplasty or a conversion from anatomical to reversed to relieve pain and restore the joint function.
• Patient has adequate quality and quantity of bone stock to support the prosthesis.

• Patient meets at least one of the following indications:

  • Advanced wear and tear of the shoulder joint resulting from degenerative, posttraumatic or rheumatoid arthritis
  • Conditions consequent to earlier operations
  • Omarthrosis or Osteoarthritis
  • Rheumatoid arthritis
  • Total joint reconstruction following trauma
• Patient has significant shoulder disability due to gross and irreparable rotator cuff deficiency. A functional deltoid muscle is necessary to use the device.
• Patient underwent reverse total shoulder reconstruction with the Anaverse Glenoid System before the date of site initiation.
• Patient has demographic, pre-operative evaluation, operative report and device information available.

Specific inclusion criteria for Conversion from Anatomical to Reversed Configuration:

• Surgery was performed with the Anaverse Glenoid System in a previously available anatomical configuration.
• Irreparable rotator cuff with superior migration of the humeral head, leading to a reduction in sub-acromial space.
• Superior tilt of the Anaverse Glenoid Baseplate not exceeding 15° compared to scapular axis.
• No evidence of mechanical or fixation failure of the Baseplate, TM Pegs or DPSC Screws, obtained pre- or intra-operatively, which would compromise the success of the conversion surgery.

Exclusion criteria:

• Patient is unwilling or unable to give consent or to comply with the follow-up program.
• Patient has any condition which would in the judgment of the Investigator place the patient at undue risk or interfere with the study.
• Patient is known to be pregnant or breastfeeding.
• Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant).
• Patient has any physical conditions that would impair adequate implant support and/or prevent the use of an appropriately sized implant.
• Patient has any sign of infection (affecting the shoulder joint or in its proximity).
• Patient has glenoid presenting with large defects due to erosion, which would lead to insufficient bony support or malalignment of the devices.
• Patient is skeletally immature.
• Patient has any sign of neuromuscular compromise (excluding rotator cuff tear).
• Patient has vascular deficiency in the affected limb in sufficient degree to endanger the success of the intervention.
• Patient has absence of musculo-ligamentous supporting structures.
• Patient suffers from joint neuropathy or other conditions that may lead to inadequate skeletal fixation.
• Patient has significant injury to the upper brachial plexus.
• Patient has non-functional deltoid muscle.

Specific exclusion criteria for Conversion from Anatomical to Reversed Configuration:

• Unstable fixation of Baseplate after removal of PE Liner.
• Superior tilt of Baseplate exceeding 15° compared to scapular axis
• Superior malposition of the Baseplate which would prevent correct assembly of the Glenosphere.
• Evidence of mechanical or fixation failure of the Baseplate, TM Pegs or DPSC Screws, obtained pre- or intra-operatively, which would compromise the success of the conversion surgery.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Anaverse Shoulder System subjects; Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed.	Device: Anaverse Shoulder System; Reverse Shoulder Arthroplasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survival of Implant System (Kaplan Meier)	The primary endpoint of this study is the survival of the implant (Reversed configuration) after 2 years, which is based on removal of the baseplate and will be determined using the Kaplan-Meier method.	2 years post-op

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Constant Murley Shoulder Score (CM)	The Constant Murley (CM) Score comprises outcome measures of freedom from pain (15 points), full range of function (20 points), active range of movement (40 points), and full strength (25 points). The total score is an aggregate of the individual outcome measures. The minimum score is 0 points (worst outcome), the maximum score possible is 100 points (best outcome).	Pre-operative (baseline), 1 year, 2 years post-operative
Subjective Shoulder Value (SSV)	The Subjective Shoulder Value (SSV) is a single point, subjective estimate of a patient's condition. The patient is asked to rate the functionality of their operated shoulder on a scale of 0% - 100% of normal.	Pre-operative (baseline), 1 year, 2 years post-operative
Radiographic Parameters	Radiographic parameters: X-rays have been evaluated for radiolucency, osteolysis, atrophy, hypertrophy, osteophytes (glenoid), component migration (humeral implant subsidence / glenoid component migration), heterotopic ossification and scapular notching	Immediate post-op to 2 years post-operative

Collaborators and Investigators

• Sponsor: Zimmer Biomet
• Investigators: Study Director: Hassan Achakri, Zimmer Biomet

Study record dates

Study Major Dates

• Study Start (Actual): May 6, 2022
• Primary Completion (Actual): April 23, 2024
• Study Completion (Actual): April 23, 2024

Study Registration Dates

• First Submitted: January 28, 2022
• First Submitted That Met QC Criteria: January 28, 2022
• First Posted (Actual): January 31, 2022

Study Record Updates

• Last Update Posted (Actual): April 8, 2025
• Last Update Submitted That Met QC Criteria: March 31, 2025
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Shoulder Injuries; Pain; Neurologic Manifestations; Musculoskeletal Diseases; Wounds and Injuries; Joint Diseases; Rupture; Tendon Injuries; Arthralgia; Rotator Cuff Injuries; Shoulder Pain
• Other Study ID Numbers: CME2017-11E

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No